A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. - Wikidata - wikimedia - TriplyDB

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

http://www.wikidata.org/entity/Q50479057

about

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging Clinical Approach to Progressive Supranuclear Palsy Key emerging issues in progressive supranuclear palsy and corticobasal degeneration The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β Freezing of gait is an early clinical feature of progressive supranuclear palsy.Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.Sample size calculations for clinical trials targeting tauopathies: a new potential disease target Glycogen synthase kinase-3: a potential preventive target for prostate cancer management Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Treatment of frontotemporal dementia.A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22.Therapy and clinical trials in frontotemporal dementia: past, present, and future.Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.Clinical trials: past, current, and future for atypical Parkinsonian syndromes.Invited review: Drug development for tauopathies.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases Further understanding of tau phosphorylation: implications for therapy.Atypical Parkinsonian syndromes: a general neurologist's perspective.Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity.The differentiation of progressive supranuclear palsy.Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies.Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Progression of brain atrophy in PSP and CBS over 6 months and 1 year.A Review of Treatment Options for Progressive Supranuclear Palsy.PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.Targeting hepatic glucose metabolism in the treatment of type 2 diabetes.Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Managing cognition in progressive supranuclear palsy.Promotion of natural tooth repair by small molecule GSK3 antagonists.New routes in frontotemporal dementia drug discovery.Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

P2860

Q26739412-03E117E1-E66D-4293-9154-78AB7C1FCA6F Q26768475-9E8ABEBF-CFBE-4CCF-BD96-787339303684 Q26772944-CB7C9EFF-E93C-419B-820F-4C622B918309 Q28084976-3BEA1C19-4733-44AB-AA41-441D111FAD36 Q28119005-1D2DE8E1-244F-4955-9647-FC1A149F074D Q28550557-3C6B04D0-5014-4F22-AB39-5B895007D9BC Q33835563-01ABAD84-A72F-40D8-9DBC-AACB678FC247 Q34031302-D8D6E505-E20F-40B1-84A1-7BBCB267ADB2 Q34487619-AE989DEC-0BCF-4200-AD01-2D95E9FDEED1 Q36070362-3B01B730-7C2F-43F7-87A7-9EF7A880FB3E Q36580561-DB904C61-4E35-44C1-BE14-E54D57EF0E3B Q36925905-ED45A261-A9A6-4F9F-8774-AAE0E5D17916 Q37035904-430C2057-2F1A-42D5-A8E2-AC2EE5CE5DFB Q37075360-D5C5886A-3D90-46A7-9701-6FB978B15486 Q37262177-A8C246ED-DE88-4194-94A0-6DC6CA80B551 Q37566888-7D07F162-4A7F-490F-BFA6-B45D7040C403 Q37621250-03C8B6A5-90A5-48B9-B801-388C4AD68680 Q38223118-BAF99702-39AA-42F7-97DB-3A3EE9A084FE Q38263698-CCB11AEC-257F-44D5-8FFE-0112E963D4E1 Q38272835-51CC9750-DA5E-45BE-8CD3-CF86EC7446F5 Q38306065-40CB3117-BD38-44CD-A083-3FA52B94F6CE Q38372272-54D220F7-F1D5-4691-8200-B7C59C7A3ED2 Q38592451-5FC57405-A1D9-4E29-BB3D-0945C59AEBCD Q38618462-1BE60AAD-2BC5-4062-B01F-364C4A1D64EB Q38625515-4E92EC4F-2CE6-480C-9250-2AF3C2985D89 Q38640294-35ED0560-6B72-4707-BC5B-1BB4999FF479 Q38666247-79062126-02FB-4828-B02D-21B1D6B3B7E7 Q38691690-185EB921-31B8-477C-8C5D-7A2FA56E4FAE Q38715233-022C877A-6E38-4386-8C11-064C231C4B8E Q38811506-3C2687C7-649E-4F29-9961-1FABD80836A3 Q38843694-BC8781E5-AF88-4DC6-95DE-A094F8C8CC33 Q38861792-3F7C88A1-E409-4248-862F-CDFD82820CB9 Q38925481-94EE34E1-6A22-41E9-BB1A-785867D976CE Q38983187-F98A15BF-D141-4F43-AB68-FB57DA366DE5 Q39003757-F87AAEAA-F70A-4A72-985F-65D1E4CFA4B8 Q39017916-CAEF2ED3-66A2-4203-9C85-45A730DA39E7 Q39032328-7BBB5CA4-6A1C-4A1D-8C14-CCDA40651282 Q39344391-0FAF9642-4683-4AB0-9240-3ABBBFCCC370 Q39669156-C3658793-83A5-49AB-A590-1913FD23B9D9 Q39771450-18F01C9E-02EB-44D0-A629-60704D45C9F2

P2860

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

http://www.wikidata.org/entity/Q50479057

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

@en

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

@nl

type

label

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

@en

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

@nl

prefLabel

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

@en

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

@nl

P1433

Q50479057-12DB1CD7-0643-49D8-8F22-54EF116CD945

P1476

Q50479057-365D81A2-4867-490D-B845-55EE90B0E374

P2093

Q50479057-08CCC3FC-7571-414D-9808-09BE1777927C

Q50479057-2D504DB5-CF75-4BCE-B83E-4143EB975077

Q50479057-42B17D7A-3808-4208-89CC-4B1FB1548D20

Q50479057-5C02200D-9A9B-4EF2-9230-8BC558A453FB

Q50479057-72885EB1-B3A5-4261-BDD1-EAA397EFA277

Q50479057-A2FF7F30-CA1C-44C0-B122-8557176860ED

Q50479057-D039A03F-B123-4F95-902C-9D854060D549

P2860

Q50479057-0987F2D3-9697-4DB1-963A-A2E779F69905

Q50479057-0BB13CEE-05D3-4A17-B5E8-36E220A099AA

Q50479057-15B0FE3F-9C1D-4D3E-8CB2-247E7B754FBC

Q50479057-1AEE1C8E-7FC5-48D0-AA3E-5CCF212D740C

Q50479057-2A9F93D2-FD7B-455D-B5D5-4476FB6ECA0D

Q50479057-2E4E9016-6247-48FB-9052-80966B7BC8A8

Q50479057-4E7FCB45-22F0-4ACF-AE4E-D141349D7DA5

Q50479057-555E7029-9F24-4268-8358-E0BE8EB7EACF

Q50479057-5F38EB02-368D-4544-8DA3-686DF45A7252

Q50479057-681D8B7B-9258-4F74-8775-088CBF33CAEB

P304

Q50479057-B4F9C3DB-C35D-4632-BD0A-65540526C345

P31

Q50479057-7576992C-33BB-4045-A001-A9F2CCC405F8

P356

Q50479057-16B4155E-2470-4094-AA2C-7EB436BA8CFF

P407

Q50479057-C058BFA7-5E98-4872-BF58-ADAE941C2291

P433

Q50479057-B24E2A97-D15E-4A4F-BADF-F88CCFFA02EA

P478

Q50479057-151859CD-F13B-4ACE-8EF9-E4B4F00444B0

P50

Q50479057-0FB09E0E-AF0D-4006-A95C-CA3AB698846E

Q50479057-89473968-CA43-45B7-B1C7-F90C0CE8D38D

Q50479057-CED7A9F5-5AE4-43F0-BB25-117400CEBF33

P577

Q50479057-668893D9-C157-4ADC-A8EB-854A75DD35A6

P5875

Q50479057-D7B67A05-DD10-465B-BA68-0F7B762BA6D0

P698

Q50479057-91A7493A-46CC-4A22-9D49-04EB6BAB667E

P921

Q50479057-548B8B20-24D6-4D04-8C42-B9DADDD1B763

P356

P1433

Movement Disorders

P1476

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

@en

P2093

Belén Gómez-Carrillo

http://www.w3.org/2001/XMLSchema#string

David Burn

http://www.w3.org/2001/XMLSchema#string

Günter U Höglinger

http://www.w3.org/2001/XMLSchema#string

María V Andrés

http://www.w3.org/2001/XMLSchema#string

TAUROS Investigators

http://www.w3.org/2001/XMLSchema#string

Teodoro Del Ser

http://www.w3.org/2001/XMLSchema#string

Teresa León

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib

CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

The timed "Up & Go": a test of basic functional mobility for frail elderly persons

The glamour and gloom of glycogen synthase kinase-3

Progressive supranuclear palsy: where are we now?

Donepezil in the treatment of progressive supranuclear palsy.

The FAB: a Frontal Assessment Battery at bedside.

Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes.

EQ-5D: a measure of health status from the EuroQol Group.

P304

470-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.25824

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Andrew John Lees

P577

2014-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262046564

http://www.w3.org/2001/XMLSchema#string

P698

24532007

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial